Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Lopez-Romero P, Fakhouri W, de la Torre I, Zaremba-Pechmann L, Holzkämper T, Fautrel B. Alten R, et al. Rheumatol Ther. 2023 Feb;10(1):73-93. doi: 10.1007/s40744-022-00500-6. Epub 2022 Oct 13. Rheumatol Ther. 2023. PMID: 36227530 Free PMC article.
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J. Hagen M, et al. Among authors: alten r. J Rheumatol. 2019 May;46(5):460-466. doi: 10.3899/jrheum.180028. Epub 2018 Dec 1. J Rheumatol. 2019. PMID: 30504510 Clinical Trial.
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).
Behrens F, Koehm M, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester GR, Feist E, Herrmann E, Kellner H, Krueger K, Lehn A, Müller-Ladner U, Rubbert-Roth A, Tony HP, Wassenberg S, Burkhardt H. Behrens F, et al. Among authors: alten r. Rheumatology (Oxford). 2021 Nov 3;60(11):5318-5328. doi: 10.1093/rheumatology/keab153. Rheumatology (Oxford). 2021. PMID: 33738492 Free PMC article. Clinical Trial.
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe.
Taylor PC, Fautrel B, Piette Y, Romero-Yuste S, Broen J, Welcker M, Howell O, Rottier E, Zignani M, Van Beneden K, Caporali R, Alten R. Taylor PC, et al. Among authors: alten r. RMD Open. 2022 Dec;8(2):e002658. doi: 10.1136/rmdopen-2022-002658. RMD Open. 2022. PMID: 36549856 Free PMC article.
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
Alten R, Nüßlein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M. Alten R, et al. RMD Open. 2017 Feb 13;3(1):e000345. doi: 10.1136/rmdopen-2016-000345. eCollection 2017. RMD Open. 2017. PMID: 28243468 Free PMC article.
233 results